Navigation Links
Molecular battle in cancer cells offers clues for treatment
Date:1/19/2011

CHAPEL HILL, N.C. Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation's discovery in 2008. The hunt is now yielding fruit. In the Jan. 18, 2011 issue of Cancer Cell, researchers reveal how the mutation contributes to cancer development and suggest potential ways to counter its effects.

About 75 percent of people with low-grade brain tumors and 20 percent of people with acute myeloid leukemia have a mutated version of a gene known as IDH. IDH helps cells metabolize, or eat, food. "We now know that IDH represents the most frequently mutated metabolic gene in human cancer. And that changes the landscape of cancer research in metabolism quite a lot," said Yue Xiong, PhD, William R. Kenan Jr. professor of biochemistry and biophysics at the UNC Lineberger Comprehensive Cancer Center.

Xiong and collaborators at UNC, the University of California San Diego, and the Shanghai Medical College of Fudan University in China discovered that the IDH mutation sets off a battle inside cells between two metabolites, small molecules produced by metabolic enzymes. On the good sidethe side that leads to normal cell growthis a molecule called ?-KG. On the bad sidethe side that leads to canceris a molecule called 2-HG.

The researchers discovered that cells with the IDH mutation produce less ?-KG and more 2-HG than normal cells. 2-HG then outcompetes ?-KG, disabling a whole family of enzymes that depend on ?-KG to do their jobs in the cell. Normal cell functions break down, contributing to the development of cancer.

Two of the affected enzymes are also involved in controlling gene expression, so if 2-HG wins the battle, it can also activate other genes that lead to cancer growth.

Bolstering ?-KG to help fight 2-HG could offer a new treatment option for patients with the mutation. "?-KG is a natural product of the body. So we know we can survive it, we know it's not toxic. That gives us a window of opportunity," said Xiong.

"In terms of future therapeutic interventions for IDH-mutated tumors, there are two directions we could go," Xiong said. "One is developing a drug that inhibits the ability of the mutant enzyme from producing 2-HG. Another is to somehow provide ?-KG back to the patients with mutated IDH to battle 2-HG."

Such therapies would help only those cancer patients with IDH mutations. "We no longer believe there will be a single silver bullet, a drug to treat and cure all types of cancers," Xiong said. "Instead, we are looking into the therapeutic treatment of individual types of cancer. Therefore, a specific agent that is targeting a very specific event such as tumor with mutated IDH now becomes much more valuable."

In 2010, more than 13,000 people died from brain and other nervous system cancers, and more than 20,000 died from leukemia. A drug that helps even a portion of patients with these cancers can still affect a lot of people, said Xiong.


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina School of Medicine
Source:Eurekalert  

Related medicine news :

1. Molecular pathways linked to sex, age affect outcomes in lung cancer
2. SNMs Conjoint Mid-Winter Meetings continue to advance molecular imaging
3. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
4. The Association for Molecular Pathology celebrates ruling in DNA patent case
5. USC researchers discover new molecular subtype of brain cancer
6. Molecular discovery points to new therapies for brain tumors
7. Molecular marker could help spot pancreatic cancer early
8. News from Molecular Medicine
9. Scientists discover the molecular heart of collective behavior
10. Salt Lake City proclaims Molecular Imaging Days during SNMs Annual Meeting in June
11. Acupunctures molecular effects pinned down
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecular battle in cancer cells offers clues for treatment
(Date:5/6/2016)... ... 06, 2016 , ... Innovations with Ed Begley Jr. announced ... 2016, via Discovery Channel. Dates and show times TBA. , AsedaSciences® was established ... through innovative cellular analysis. In this segment, viewers will learn how AsedaSciences utilizes ...
(Date:5/6/2016)... , ... May 06, 2016 , ... From May 4 ... IL, offering EarQ members the unique opportunity to learn more about Signia’s technology and ... practice growth. , “It is our priority to see practices succeed in this highly ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... Sleepopolis.com . , Since launching in September, 2014 Sleepopolis has resided at ... areas, which now include pillows, sheets, mattress toppers, bed frames, and more. , ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor of Military Spouse ... training, and the National Military Family Association, a nonprofit that works to strengthen ... full-tuition scholarship recipient of 2016. , “Being awarded this scholarship by Career ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... President at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers ... - an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK will ... extending care beyond the implant at the Heart Rhythm ... in San Francisco . ... the highest quality of patient care and satisfaction possible. ... for each and every tomorrow," said Marlou Janssen ...
(Date:5/3/2016)... , May 3, 2016 Pharmaceutical ... $55 million to a woman who says its talc-based ... awarded Gloria Ristesund $5 million in compensatory ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... against the company. In February, the same court awarded ...
Breaking Medicine Technology: